Financial PerformanceMGX reported a net loss per share that was better than consensus estimates, reflecting stronger financial performance than expected.
Gene Therapy DevelopmentMGX-001 demonstrated durable FVIII activity in non-human primates for over 12 months, setting it apart from competitors.
Strategic PartnershipsMGX is on track for one to two development candidate nominations from its Ionis collaboration in 2025, indicating strong progress in their partnership initiatives.